Multicell Technologies IncOver The Counter Market:MCET
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (-90.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range
- 52 Week Range
- Volume10,800
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MCET |
|---|---|---|
| 12:14 ET | 10000 | 1E-06 |
| 03:43 ET | 800 | 1E-06 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Multicell Technologies Inc | 50.0K | 0.0x | --- |
Stromacel Inc | 10.0 | 0.0x | --- |
US Stem Cell Inc | 64.2K | 0.0x | --- |
Cell Kinetics Ltd | 2.0K | 0.0x | --- |
BioSyntech Inc | 120.0 | 0.0x | --- |
Trex Wind-Down Inc | 690.0 | 0.0x | --- |
Company Information
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
Contact Information
- Headquarters
- 68 Cumberland Street, Suite 301WOONSOCKET, RI, United States 02865
- Phone
- 401-762-0045
- Fax
- 401-762-0098
Executives
- Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
- W. Gerald Newmin
- Director
- Stephen Chang
- Director
- Grant Miller
- Independent Director
- Thomas Page
- Independent Director
- Edward Sigmond
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.0K |
|---|---|
Revenue (TTM) | $805.2K |
Shares Outstanding | 5.0B |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.00 |
Book Value | $0.00 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | 1.0x |
Operating Margin | -33.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
